Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Cancer Immunotherapy Market

Cancer Immunotherapy Market Analysis

  • Report ID: GMI9584
  • Published Date: May 2024
  • Report Format: PDF

Cancer Immunotherapy Market Analysis

Based on product, the market is divided into monoclonal antibodies, immunomodulators, cancer vaccines, oncolytic viral therapies, and cytokines. Further, immunomodulators are segmented into checkpoint inhibitors, immune checkpoint modulators, and other immunomodulators. The monoclonal antibodies segment is forecasted to reach USD 119.6 billion by 2032, displaying robust growth propelled by several key factors.


  • Monoclonal antibodies are designed to target specific proteins or antigens present on cancer cells. This specificity enables them to selectively bind to cancer cells while sparing normal, healthy cells, minimizing off-target effects and reducing toxicity compared to traditional chemotherapy.
  • Some monoclonal antibodies function by activating the immune system's anti-tumor response. For example, immune checkpoint inhibitors block proteins like PD-1 or CTLA-4, allowing T cells to recognize and attack cancer cells more effectively.
  • Further, biomarkers such as PD-L1 expression levels can help identify patients who are most likely to benefit from monoclonal antibody therapy. This allows for personalized treatment strategies tailored to individual patients based on their tumor biology and immune profile, thereby fueling market growth.
Cancer Immunotherapy Market, By Cancer Type (2023)

Based on cancer type, the cancer immunotherapy market is bifurcated into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, pancreatic cancer, and other cancer types. The breast cancer segment accounted for USD 19.5 billion in 2023.

  • Certain subtypes of breast cancer such as triple-negative breast cancer (TNBC) and HER2-positive breast cancer, exhibit higher levels of tumor-infiltrating lymphocytes (TILs) and tumor-associated antigens. These characteristics make breast tumors more susceptible to immunotherapy interventions, as they provide targets for the immune system to recognize and attack cancer cells.
  • Immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, have shown promise in treating breast cancer, particularly in TNBC and HER2-positive subtypes. These subtypes often have higher levels of immune checkpoint expression, suggesting that they may be more responsive to checkpoint blockade.
  • Immunotherapy can be combined with other treatment modalities commonly used in breast cancer management such as chemotherapy, targeted therapy (e.g., HER2-targeted therapy), and radiation therapy. These combination approaches have the potential to enhance treatment efficacy, overcome resistance mechanisms, and improve patient outcomes. Thus, propelling the growth of the market.

Based on end-use, the cancer immunotherapy market is bifurcated into hospitals, specialty clinics, and cancer research centres. The hospitals segment accounted for USD 78.6 billion in 2023.

  • Hospitals typically have multidisciplinary teams of oncologists, surgeons, radiologists, pathologists, and immunologists who collaborate to provide comprehensive cancer care. This integrated approach ensures that patients receive personalized treatment plans tailored to their specific needs, including the incorporation of immunotherapy when appropriate.
  • They often have access to specialized expertise in cancer immunotherapy, including physicians, nurses, and researchers with extensive experience in immunology and oncology. This expertise allows for the effective management of complex cases and the implementation of cutting-edge immunotherapy protocols.
  • Further, hospitals are equipped with state-of-the-art infrastructure and facilities necessary for the administration and monitoring of cancer immunotherapy. This includes infusion centers, radiology departments for imaging studies, pathology laboratories for biomarker testing, and specialized units for managing potential immune-related adverse events.
North America Cancer Immunotherapy Market, 2021- 2032 (USD Billion)

The U.S. cancer immunotherapy market is forecasted to reach USD 115.2 billion by 2032.

  • The U.S. is home to world-renowned research institutions, academic medical centres, and biopharmaceutical companies at the forefront of cancer immunotherapy research and innovation. These institutions drive advancements in immunotherapy approaches, biomarker development, and clinical trial initiatives, contributing to the expansion of treatment options and improved patient outcomes.
  • The increasing prevalence of cancer in U.S. is driving substantial growth in the cancer immunotherapy industry. For instance, according to the Centers for Disease Control and Prevention (CDC) in 2020, there were 1,603,844 new cases of cancer reported, with 602,347 individuals losing their lives to this disease, in U.S.

The cancer immunotherapy market in UK is expected to experience significant and promising growth from 2024 to 2032.

  • The UK hosts a robust biopharmaceutical industry with companies specializing in drug discovery, development, and manufacturing. These companies collaborate with academic institutions and research organizations to translate scientific discoveries into clinical therapies, contributing to the growth of the market.

Japan cancer immunotherapy market is anticipated to witness lucrative growth between 2024 – 2032.

  • Japan has a well-established regulatory framework for drug approval. The Pharmaceuticals and Medical Devices Agency (PMDA) ensures rigorous evaluation of new therapies while also facilitating timely approvals for promising treatments. This regulatory efficiency can accelerate the introduction of cancer immunotherapies to the market.

The cancer immunotherapy market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.

  • With a growing population and increasing healthcare expenditure, Saudi Arabia represents a potentially lucrative market for cancer immunotherapy companies. As awareness of immunotherapy grows and access to advanced treatments improves, the demand for these therapies is likely to increase.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of cancer immunotherapy reached USD 125.7 billion in 2023 and is set to witness 9.3% CAGR from 2024 to 2032, led by rising prevalence of cancer.

The monoclonal antibodies product segment will reach USD 119.6 billion in revenue by 2032, as they are designed to target specific proteins or antigens present on cancer cells.

U.S. market size will record USD 115.2 billion by 2032, owing to the presence of world-renowned research institutions, academic medical centers, and biopharmaceutical companies at the forefront of cancer immunotherapy research and innovation.

AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., and GSK plc among others.

Cancer Immunotherapy Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 125
  • Tables & Figures: 233
  • Countries covered: 23
  • Pages: 180
 Download Free Sample